Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

An autopsy case of widespread brain dissemination of glioblastoma unnoticed by magnetic resonance imaging after treatment with bevacizumab.

Hardian RF, Goto T, Kuwabara H, Hanaoka Y, Kobayashi S, Kanno H, Shimojo H, Horiuchi T, Hongo K.

Surg Neurol Int. 2019 Jul 5;10:137. doi: 10.25259/SNI-183-2019. eCollection 2019.

2.

[Bevacizumab-Related Hyperintense Lesions on Diffusion-Weighted Imaging at Different Locations in a Patient with Malignant Glioma].

Oshiro S, Wakuta N, Kawai S, Miki K, Shigemori Y.

No Shinkei Geka. 2017 Jun;45(6):509-517. doi: 10.11477/mf.1436203541. Japanese.

PMID:
28634311
3.

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.

Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, Karikari IO, Grossi PM, Thomas S, Friedman AH, Adamson C.

J Neurosurg. 2016 Apr;124(4):998-1007. doi: 10.3171/2015.4.JNS142200. Epub 2015 Oct 9.

PMID:
26452121
4.

Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.

PMID:
25594327
5.

Molecular analysis of a recurrent glioblastoma treated with bevacizumab.

Furuta T, Nakada M, Misaki K, Sato Y, Hayashi Y, Nakanuma Y, Hamada J.

Brain Tumor Pathol. 2014 Jan;31(1):32-9. doi: 10.1007/s10014-013-0142-4. Epub 2013 Mar 17.

PMID:
23504126
6.

Disseminated progression of glioblastoma after treatment with bevacizumab.

Bloch O, Safaee M, Sun MZ, Butowski NA, McDermott MW, Berger MS, Aghi MK, Parsa AT.

Clin Neurol Neurosurg. 2013 Sep;115(9):1795-801. doi: 10.1016/j.clineuro.2013.04.017. Epub 2013 May 21.

7.

Diffusely Infiltrating Cerebellar Anaplastic Astrocytoma Effectively Controlled with Bevacizumab: Case Report and Literature Review.

Kohzuki H, Matsuda M, Miki S, Shibuya M, Ishikawa E, Matsumura A.

World Neurosurg. 2018 Jul;115:181-185. doi: 10.1016/j.wneu.2018.04.110. Epub 2018 Apr 26. Review.

PMID:
29704688
8.

Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.

Akiyama Y, Kimura Y, Enatsu R, Mikami T, Wanibuchi M, Mikuni N.

World Neurosurg. 2018 May;113:e508-e514. doi: 10.1016/j.wneu.2018.02.070. Epub 2018 Feb 21.

PMID:
29476996
9.

[Glioblastoma multiforme developing separately from the initial lesion 9 years after successful treatment for gliomatosis cerebri: a case report].

Inoue T, Kanamori M, Sonoda Y, Watanabe M, Sasajima T, Kamisato N, Kumabe T, Tominaga T.

No Shinkei Geka. 2008 Aug;36(8):709-15. Review. Japanese.

PMID:
18700534
10.

Predictive significance of mean apparent diffusion coefficient value for responsiveness of temozolomide-refractory malignant glioma to bevacizumab: preliminary report.

Nagane M, Kobayashi K, Tanaka M, Tsuchiya K, Shishido-Hara Y, Shimizu S, Shiokawa Y.

Int J Clin Oncol. 2014 Feb;19(1):16-23. doi: 10.1007/s10147-013-0517-x. Epub 2013 Jan 26.

PMID:
23354833
11.

[Combination Therapy with Radiation, Temozolomide, and Bevacizumab after Partial Tumor Removal in Glioblastoma Patients with Low Performance Status].

Nakao J, Ishikawa E, Matsuda M, Yamamoto T, Takano S, Matsumura A.

Gan To Kagaku Ryoho. 2017 Jun;44(6):495-500. Japanese.

PMID:
28698441
12.

Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H, Quiñones-Hinojosa AR.

J Neurosurg. 2009 Jan;110(1):156-62. doi: 10.3171/2008.4.17536.

PMID:
18847342
13.

Radiographic patterns of relapse in glioblastoma.

Chamberlain MC.

J Neurooncol. 2011 Jan;101(2):319-23. doi: 10.1007/s11060-010-0251-4. Epub 2010 Jun 10.

PMID:
21052776
14.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
15.

Achievement of three year remission with bevacizumab and irinotecan in recurrent glioblastoma multiforme: a case report.

Vivekanandarajah A, Krishnarasa B, Mourad M, Aoun N, Odaimi M.

Clin Med Insights Oncol. 2011 Feb 14;5:15-21. doi: 10.4137/CMO.S6525.

16.

Time course of imaging changes of GBM during extended bevacizumab treatment.

Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB.

J Neurooncol. 2008 Jul;88(3):339-47. doi: 10.1007/s11060-008-9573-x. Epub 2008 Apr 4.

PMID:
18389177
17.

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.

Burger MC, Mildenberger IC, Wagner M, Mittelbronn M, Steinbach JP, Bähr O.

Int J Mol Sci. 2017 Mar 29;18(4). pii: E726. doi: 10.3390/ijms18040726.

18.

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY.

Oncologist. 2018 May;23(5):524-e44. doi: 10.1634/theoncologist.2017-0689. Epub 2018 Feb 22.

19.

Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.

Heiland DH, Masalha W, Franco P, Machein MR, Weyerbrock A.

J Neurooncol. 2016 Feb;126(3):567-75. doi: 10.1007/s11060-015-2002-z. Epub 2015 Nov 27.

PMID:
26614518
20.

Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma.

Otani Y, Ichikawa T, Uneda A, Kurozumi K, Ishida J, Date I.

World Neurosurg. 2018 Aug;116:464-471.e1. doi: 10.1016/j.wneu.2018.05.036. Epub 2018 May 14.

PMID:
29772361

Supplemental Content

Support Center